Market Watch
08 Jun 2026, 08:44 UTC · 4h ago
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
Search tags
Market Watch
08 Jun 2026, 08:44 UTC · 4h ago
Search tags
Story key points
2 claims · impact-rated
A late-stage trial for Zealand Pharma's weight-loss drug showed many patients discontinued use due to tolerability problems. — Failure or poor tolerability in late-stage trials significantly reduces the probability of regulatory approval and future revenue for a primary product candidate.
-0.80Zealand Pharma's market value decreased by 20% on Monday following the trial results. — A sharp drop in market cap reflects immediate investor loss of confidence and a repricing of the company's valuation.
-0.40Ticker attribution
Model heads
The company lost 20% of its market value following negative results regarding drug tolerability in a late-stage trial.
Continue reading
3 related stories
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
5 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
Reuters
5h ago
